Based on the key indicators related to Jasper Therapeutics' liquidity, profitability, solvency, and operating efficiency, Jasper Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Jasper Therapeutics' Total Stockholder Equity is fairly stable compared to the past year. Other Current Assets is likely to climb to about 1.9 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 3.7 M in 2024. Key indicators impacting Jasper Therapeutics' financial strength include:
The financial analysis of Jasper Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Jasper Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(61.24 Million)
Jasper
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Investments
Depreciation
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Non Current Liabilities Other
Short Long Term Debt Total
Property Plant And Equipment Net
Net Receivables
Common Stock Shares Outstanding
Capital Lease Obligations
Net Invested Capital
Property Plant And Equipment Gross
Net Working Capital
Depreciation And Amortization
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Interest Expense
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Jasper Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Jasper Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Jasper Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Jasper Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Jasper Therapeutics. Check Jasper Therapeutics' Beneish M Score to see the likelihood of Jasper Therapeutics' management manipulating its earnings.
Jasper Therapeutics Stock Summary
Jasper Therapeutics competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Jasper Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Jasper Therapeutics's current stock value. Our valuation model uses many indicators to compare Jasper Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jasper Therapeutics competition to find correlations between indicators driving Jasper Therapeutics's intrinsic value. More Info.
Jasper Therapeutics is rated second overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . At this time, Jasper Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Jasper Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Jasper Therapeutics Systematic Risk
Jasper Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Jasper Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Jasper Therapeutics correlated with the market. If Beta is less than 0 Jasper Therapeutics generally moves in the opposite direction as compared to the market. If Jasper Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Jasper Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Jasper Therapeutics is generally in the same direction as the market. If Beta > 1 Jasper Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Jasper Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Jasper has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Jasper Therapeutics' financials are consistent with your investment objective using the following steps:
Review Jasper Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Jasper Therapeutics' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Jasper Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Jasper Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Jasper Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Jasper Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Jasper Therapeutics growth as a starting point in their analysis.
Jasper Therapeutics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Jasper Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Jasper Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Jasper Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Jasper Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Jasper Therapeutics's daily price indicators and compare them against related drivers.
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.